Clinical observation of Yiqi Qingdu Prescription(益气清毒方)on the treatment of intermediate-stage and advanced non-small-cell lung cancer

作     者：LIANG Qijun TANG Xiaoling YU Jiong XIONG Monian ZHU Huifang XIONG Linkai ZENG Ru YU Peiwen LIANG Qijun;TANG Xiaoling;YU Jiong;XIONG Monian;ZHU Huifang;XIONG Linkai;ZENG Ru;YU Peiwen

作者机构：Department of RespiratoryAffiliated Hospital of Jiangxi University of Traditional Chinese MedicineNanchang 330006China Department of OncologyAffiliated Hospital of Jiangxi Institute of Traditional Chinese MedicineNanchang 330046China Key Laboratory of Yiqi Qingdu for Malignant TumorJiangxi Institute of Traditional Chinese MedicineNanchang 330046China School of clinical medicineJiangxi University of Traditional Chinese MedicineNanchang 330004China Second Department of Internal MedicineJiangxi Tumor HospitalNanchang 330029China 

出 版 物：《Journal of Traditional Chinese Medicine》 (中医杂志（英文版）)

年 卷 期：2021年第41卷第2期

页      面：308-315页

核心收录：

学科分类：1008[医学-中药学(可授医学、理学学位)] 1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学] 

基　　金：Supported by Xiong Monian National Famous and Senior Chinese Medicine Experts Inheritance Studio Construction Project(No.47,the Personnel and Education Department of the State Administration of Traditional Chinese Medicine promulgated) Key R&D projects in Jiangxi Province:lung cancer prevention and treatment,health preservation technology and products based on the method of"Tonifying Qi and Cleaning Toxin"(No.20171BBG70113) 

主　　题：carcinoma,non-small-cell lung integrative medicine therapeutic uses carcinoembryonic antigen antigens,differentiation,T-lymphocyte Yiqi Qingdu prescription 

摘      要：OBJECTIVE:To observe the effects of the Yiqi Qingdu prescription(益气清毒方)on intermediate-stage and advanced non-small-cell lung cancer(NSCLC).METHODS:In total,300 patients with intermediate-stage or advanced NSCLC were randomly and equally divided into three groups using computer-generated random numbers as follows:Western medicine(WM),Chinese medicine(CM),and integrated Traditional Chinese and Western Medicine(IM).After 3 months of treatment,the overall response rate(ORR);disease control rate(DCR);symptom score(SS);Karnofsky performance status(KPS);adverse event score;counts of CD3^(+),CD4^(+),and CD8^(+)cells;CD4^(+)/CD8^(+)ratio;and carcinoembryonic antigen(CEA)level were compared among the ***:The ORRs were 30.36%,20.24%,and 7.87%in the IM,CM,and WM groups,respectively,whereas the DCRs were 85%,75%,and 73%,*** to the CM group,the ORR was significantly higher in the WM and IM groups,whereas the DCR was significantly higher in the IM group(all P0.05).SS was obviously higher in the WM group than in the other two groups(both P0.01).KPS was significantly lower in the WM group after treatment(P=0.005).The mean number of adverse events was significantly lower in the CM(2.2±1.3)and IM(2.4±1.3)groups than in the WM group(4.6±1.7,both P0.05).CD3^(+)cell counts were significantly decreased in the WM group(P=0.031).In the IM group,CD8^(+)cell counts were increased after treatment,whereas the CD4^(+)/CD8^(+)ratio was decreased(both P0.01).Compared with the WM group,CD3^(+)(P=0.01),CD4^(+)(P=0.044),and CD8^(+)(P=0.009)cell counts were significantly higher in the IM group,whereas the CD4^(+)/CD8^(+)ratio was significantly lower(P=0.011).Relative to the CM group,CD8^(+)cell counts were significantly higher(P=0.001)and the CD4^(+)/CD8^(+)ratio was significant ly lower in the IM group(P=0.001).CEA levels were significantly increased in the CM group(P=0.023).CONCLUSION:The Yiqi Qingdu prescription can improve the outcomes of WM in patients with NSCLC